TACROLIMUS - DACLIZUMAB - MYCOPHENOLATE MOFETIL IMMUNE PROPHYLAXIS IN PEDIATRIC LIVER TRANSPLANTATION. An open, pilot, investigator-driven study in 20 recipients.

Trial Profile

TACROLIMUS - DACLIZUMAB - MYCOPHENOLATE MOFETIL IMMUNE PROPHYLAXIS IN PEDIATRIC LIVER TRANSPLANTATION. An open, pilot, investigator-driven study in 20 recipients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Mar 2018

At a glance

  • Drugs Daclizumab (Primary) ; Mycophenolate mofetil (Primary) ; Tacrolimus (Primary)
  • Indications Liver transplant rejection
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 09 Mar 2018 This study has been completed in Belgium.
    • 10 Jun 2017 Biomarkers information updated
    • 26 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top